Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.
$6.03+3.08%
报价 2026-11-06
市值
$780.5M
EV
$2.95B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -80.1%
$5.05$30.30
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ALMSAlumis Inc. Common Stock | $780.5M | +3.1% | -65.8% | 89.6% | – | – | – | |
| ETONEton Pharmaceuticals, Inc. | $1.61B | +19.7% | +36.7% | 69.2% | 32.0x | 35.6x | 42.2x | |
| OMEROmeros Corporation | $1.22B | -0.9% | +2728.0% | 95.8% | 9.7x | 10.7x | – | |
| LXRXLexicon Pharmaceuticals, Inc. | $792M | +10.6% | -19.6% | 98.6% | – | – | – | |
| OCGNOcugen, Inc. | $313.7M | +13.3% | -33.9% | 88.5% | – | – | – | |
| FULCFulcrum Therapeutics, Inc. | $282.3M | +0.5% | -98.9% | 0% | – | – | – | |
| LCTXLineage Cell Therapeutics, Inc. | $258M | +3.8% | – | – | – | – | – | |
| BCYCBicycle Therapeutics plc | $253M | +3.7% | – | 100% | – | – | – | |
| ADCTADC Therapeutics S.A. | $201.7M | -3.7% | – | 88.8% | – | – | – | |
| 同行中位数 | – | – | -19.6% | 88.8% | 20.8x | 23.1x | 42.2x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。